Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 8562
Gene Symbol: DENR
DENR
0.020 AlteredExpression disease BEFREE Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. 31838085 2020
Entrez Id: 7402
Gene Symbol: UTRN
UTRN
0.020 AlteredExpression disease BEFREE Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. 31838085 2020
Entrez Id: 10059
Gene Symbol: DNM1L
DNM1L
0.020 AlteredExpression disease BEFREE Moreover, we found that increased DRP1 expression was indicative of poor prognosis in patients with castration-resistant PCa. 31838085 2020
Entrez Id: 1400
Gene Symbol: CRMP1
CRMP1
0.020 AlteredExpression disease BEFREE Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. 31838085 2020
Entrez Id: 23604
Gene Symbol: DAPK2
DAPK2
0.010 AlteredExpression disease BEFREE Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. 31838085 2020
Entrez Id: 2950
Gene Symbol: GSTP1
GSTP1
0.100 GeneticVariation disease BEFREE Functional inactivation of GSTP1 increases the susceptibility to oxidative stress and enhance progression risk of the prostatic carcinoma. 31837464 2020
Entrez Id: 429
Gene Symbol: ASCL1
ASCL1
0.010 Biomarker disease BEFREE hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen. 31836808 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE Here we describe the efficacy of <sup>18</sup>F-labelled radiohybrid PSMA, rhPSMA-7, a novel theranostic PSMA-targeting agent for imaging BCR of prostate cancer. 31836682 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE 68Ga-Prostate-Specific Membrane Antigen PET/CT Findings in Extra-axial Metastasis From Prostate Carcinoma. 31833925 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Our findings illustrate a previously unknown regulatory mechanism in prostate cancer cell proliferation regulated by the MSI2-AR axis and provide novel evidence towards a strategy against prostate cancer. 31833612 2020
Entrez Id: 124540
Gene Symbol: MSI2
MSI2
0.010 Biomarker disease BEFREE Our findings illustrate a previously unknown regulatory mechanism in prostate cancer cell proliferation regulated by the MSI2-AR axis and provide novel evidence towards a strategy against prostate cancer. 31833612 2020
Entrez Id: 407043
Gene Symbol: MIR7-1
MIR7-1
0.010 Biomarker disease BEFREE MicroRNA-7-5p (miR-7-5p) has been demonstrated to be a tumor suppressor in breast cancer, hepatocarcinoma, prostate cancer and glioblastoma multiforme (GBM). 31832068 2019
Entrez Id: 407045
Gene Symbol: MIR7-3
MIR7-3
0.010 Biomarker disease BEFREE MicroRNA-7-5p (miR-7-5p) has been demonstrated to be a tumor suppressor in breast cancer, hepatocarcinoma, prostate cancer and glioblastoma multiforme (GBM). 31832068 2019
Entrez Id: 407044
Gene Symbol: MIR7-2
MIR7-2
0.010 Biomarker disease BEFREE MicroRNA-7-5p (miR-7-5p) has been demonstrated to be a tumor suppressor in breast cancer, hepatocarcinoma, prostate cancer and glioblastoma multiforme (GBM). 31832068 2019
Entrez Id: 2194
Gene Symbol: FASN
FASN
0.100 Biomarker disease BEFREE Here, we show that the abilities of FASN and MAGL to promote nuclear receptor activation and PCa metastasis are critically dependent upon co-expression of FABP5 in vitro and in vivo. 31831821 2019
Entrez Id: 2171
Gene Symbol: FABP5
FABP5
0.060 Biomarker disease BEFREE Our findings position FABP5 as a key driver of lipid-mediated metastasis and suggest that disruption of lipid signaling via FABP5 inhibition may constitute a new avenue to treat metastatic PCa. 31831821 2019
Entrez Id: 11343
Gene Symbol: MGLL
MGLL
0.020 Biomarker disease BEFREE Here, we show that the abilities of FASN and MAGL to promote nuclear receptor activation and PCa metastasis are critically dependent upon co-expression of FABP5 in vitro and in vivo. 31831821 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 AlteredExpression disease BEFREE PSMA-targeted alpha therapy (TAT) has shown early signs of activity in patients with prostate cancer (PrCa) refractory to beta radiation. 31831560 2019
Entrez Id: 2078
Gene Symbol: ERG
ERG
0.100 AlteredExpression disease BEFREE Since the discovery of the TMPRSS2-ERG fusion transcript in prostatic carcinoma (PCa) more than ten years ago, a long list of recurrent genomic rearrangements involving other transcription factors of the ETS family has been described. 31831298 2020
Entrez Id: 5888
Gene Symbol: RAD51
RAD51
0.090 GeneticVariation disease BEFREE The WRN protein along with ATM, BRCA1, BRCA2, and RAD51 among others, comprise a DNA repair system by homologous recombination, and its alterations are associated with forms of hereditary PCa. 31831298 2020
Entrez Id: 2130
Gene Symbol: EWSR1
EWSR1
0.020 AlteredExpression disease BEFREE Although the expression of EWSR1 appears to be necessary for the oncogenic effects of ETS factors, the EWSR1-ETS rearrangement has never been reported in PCa. 31831298 2020
Entrez Id: 7486
Gene Symbol: WRN
WRN
0.010 GeneticVariation disease BEFREE The WRN protein along with ATM, BRCA1, BRCA2, and RAD51 among others, comprise a DNA repair system by homologous recombination, and its alterations are associated with forms of hereditary PCa. 31831298 2020
Entrez Id: 54738
Gene Symbol: FEV
FEV
0.010 GeneticVariation disease BEFREE Prostatic carcinoma with neuroendocrine differentiation harboring the EWSR1-FEV fusion transcript in a man with the WRN G327X germline mutation: A new variant of prostatic carcinoma or a member of the Ewing sarcoma family of tumors? 31831298 2020
Entrez Id: 2833
Gene Symbol: CXCR3
CXCR3
0.040 AlteredExpression disease BEFREE Meanwhile, a positive correlation of E-cadherin and CXCR3-B expression was found both in experimental PCa liver micro-metastases and patients' tissue. 31831069 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE This study aims to assess the diagnostic efficacy of 68Ga PSMA PET-CT in local lymph node staging of high risk primary prostate cancer when compared to histopathological findings following radical prostatectomy with pelvic lymph node dissection. 31829288 2019